Bao Chai

Bao Chai


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
CYCHENGBIN YANG
CHENGBIN YANG
XGXiangyu Gan
Xiangyu Gan
YZYuping Zeng
Yuping Zeng
ZXZhourui Xu
Zhourui Xu
LXLongqian Xu
Longqian Xu
YCYujuan Chai
Yujuan Chai

17 October 2023 in Dermatology
Verified
Journal Article
Open access
PDF file
FWFen Wei
Fen Wei
LLLi Li
Li Li
YKYi Kong
Yi Kong
XYXiaofeng Yan
Xiaofeng Yan
KVKevin J. Varghese
Kevin J. Varghese
HCHongxiang Chen
Hongxiang Chen
Background: Rosacea is a chronic inflammatory dermatological condition in humans, and its pathogenesis remains unclear. However, the development of rosacea is suspected to be related to Demodex, a microscopic commensal organism that resides in or near hair follicles and sebaceous glands. Although Demodex is known to be a host-specific, obligate commensal organism, it is currently difficult to be cultured in vitro to parasitize and infect other animal hosts. Therefore, direct evidence for a pathogenic role of Demodex in rosacea is currently lacking. Summary: As circumstantial evidence, non-invasive skin-detecting techniques have shown abnormally elevated numbers of Demodex in rosacea patients. Increased cytokine levels such as IL-10, IL-8, and IL-12p70 have been observed in human sebocytes following the Demodex challenge, and acaricides have been found to be effective in rosacea therapy, all point to a close relationship between Demodex and rosacea. Based on these findings, we conducted a comprehensive literature review to summarize the current state of knowledge, research insights, and clinical treatment recommendations for Demodex-associated rosacea, with the ultimate goal of improving patient outcomes.

20 February 2024 in Analytica Chimica Acta
Verified
Journal Article
Closed access
YZYuping Zeng
Yuping Zeng
XGXiangyu Gan
Xiangyu Gan
ZXZhourui Xu
Zhourui Xu
XHXiaoxiang Hu
Xiaoxiang Hu
CHChenxuan Hu
Chenxuan Hu
YCYujuan Chai
Yujuan Chai

8 August 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JJJian Jiang
Jian Jiang
YZYinlian Zhang
Yinlian Zhang
YKYi Kong
Yi Kong
QLQingtian Luo
Qingtian Luo
YHYunqing Hou
Yunqing Hou
HCHongxiang Chen
Hongxiang Chen

1 May 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
XWXueting Wang
Xueting Wang
XLXuemei Li
Xuemei Li
DLDuoyun Li
Duoyun Li
YZYiying Zhang
Yiying Zhang
BBBing Bai
Bing Bai
ZWZewen Wen
Zewen Wen
Introduction: Long non-coding RNAs (lncRNAs) are increasingly recognized as key regulators in cellular processes, including the DNA damage response (DDR). In Saccharomyces cerevisiae, DDR is critical for maintaining genomic integrity under stress, mediated by proteins like Mec1 and Rad53. However, the involvement of lncRNAs in DDR pathways, remains largely unexplored. This study investigates the function of a novel lncRNA, YIL163C, in promoting cell survival and genomic stability under DNA damage conditions.Methods: Genetic suppressor screening was employed to assess the role of YIL163C in rescuing lethality in mec1Δ sml1Δ and rad53Δ sml1Δ exposed to DNA damage. Proteomic and phosphoproteomic analyses were conducted to evaluate changes in protein abundance and phosphorylation states. The impact of YIL163C on DDR and antifungal drug tolerance, specifically to 5-fluorocytosine, was also examined.Results: Overexpression of YIL163C was found to rescue lethality in mec1Δ sml1Δ and rad53Δ sml1Δ under DNA damage conditions. Proteomic analyses revealed that YIL163C modulates pathways related to DNA replication, ER stress response, and ribosome biogenesis, enhancing cellular resilience to HU-induced stress. Additionally, YIL163C reduced sensitivity to 5-fluorocytosine, indicating a role in antifungal drug tolerance. Phosphoproteomic data suggested YIL163C influences phosphorylation states, potentially acting downstream of the Mec1-Rad53 signaling pathway.Conclusion: This study provides new insights into the regulatory mechanisms of lncRNAs in DDR, with broader implications for antifungal therapy and genomic stability research, emphasizing the role of lncRNAs in stress responses beyond traditional protein-centric mechanisms.

14 May 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
JMJunhua Ma
Junhua Ma
YXYuqing Xia
Yuqing Xia
JLJintuan Lin
Jintuan Lin
CCChengchun Chen
Chengchun Chen
QMQingyin Meng
Qingyin Meng
ZWZewen Wen
Zewen Wen
Methicillin-resistant Staphylococcus aureus (MRSA) poses a persistent clinical threat due to limited therapeutic options and the rapid emergence of resistance. Azeliragon, an orally bioavailable Receptor for Advanced Glycation End-products (RAGE) inhibitor previously tested in human trials, was identified as a potential antibacterial agent against MRSA through high-throughput screening. It exhibited potent antibacterial activity against clinical S. aureus isolates (MIC50 = 6.25 μM/3.3 μg/mL) and significantly inhibited biofilm formation. Metabolomics and proteomics suggested perturbation of lipid pathways and potential interaction with MurA. Target validation using Drug Affinity Responsive Target Stability (DARTS), Determination of biomolecular affinity by bio-layer interferometry (BLI), Limited proteolysisemass spectrometry (LiP-MS), and site-directed mutagenesis provided biochemical evidence supporting MurA as an intracellular target. Whole Genome Sequencing of resistant derivatives revealed Single Nucleotide Polymorphisms (SNPs) in cell-wall and fatty-acid efflux regulators including yycH, farE/farR, consistent with membrane and cell-wall perturbation. In a murine wound model Azeliragon reduced local bacterial burden and accelerated healing to levels comparable with vancomycin. Azeliragon is a repurposable antibacterial agent that perturbs membrane phospholipid homeostasis and engages MurA-dependent peptidoglycan synthesis. These findings support further preclinical development of Azeliragon or optimized derivatives as potential therapeutics against MRSA and other gram-positive pathogens.